Program Description

The World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC), now in its 17th year, is a unique and exciting multidisciplinary CME program. The Congress is the premiere global meeting dedicated to diabetes, obesity, lipids, cardiovascular disease (CVD), and energy balance, linking basic research to clinical practice in pursuit of our theme: Exploring New Frontiers in Metabolism — Tomorrow’s Clinical Science Today.

For nearly two decades, WCIRDC has brought researchers, physicians- clinicians and other healthcare professionals together for a distinctive international program that bridges the latest developments from bench-to-bedside. “I heard it first at the Congress” is a frequent remark from the audience over the years, many of whom attend year after year. Researchers present their latest data and findings on everything from biomarkers to new physiological insights to new ideas for therapies. WCIRDC offers attendees a unique experience to interact in an intimate setting with the distinguished global faculty for a collaborative experience that explores the newest understanding of metabolic diseases and the development of future therapeutic modalities.

Since Dr. Gerald Reaven’s pioneering work crystallized the relationship between insulin resistance (IR), diabetes, and CVD, the Congress’ focus has expanded to cover fat cells, lipids, the kidney, fatty liver, the brain, bone and energy metabolism, inflammation, aging, diet, cancer and more.  The Congress addresses dyslipidemia, atherosclerosis, hypertension, and hypercoagulation as well as new pharmaceutical interventions such as incretins, SGLT2i’s, PCSK9i’s and EPA omega 3 to name a few. The goal is to understand the state-of-the-art pathophysiology new medical interventions and to develop appropriate comprehensive clinical management strategies.

For primary care clinicians, the Congress will feature a series of workshops and “meet the expert” panels addressing the clinical prevention and management of kidney disease, diabetes, obesity, lipids, the high risk CVD, CHF patient and more. To make basic and clinical research topics relevant to clinical medicine, following the presentations, including basic research, there will be commentaries on clinical implications to practice by recognized global experts. The Congress’ intimate setting promotes personal contacts between participants and the distinguished global faculty wherein everyone learns from the free flow of questions, personal observations and face to face informal discussions.

The Congress attracts state-of-the-art abstracts by young, upcoming and recognized leaders from around the globe. These abstracts will be published in Metabolism: Clinical and Experimental, a peer-reviewed journal published twelve times a year with over 40,000 unique monthly viewers worldwide that is in the top 10% of endocrinology, diabetes, and metabolism journals (https://www.metabolismjournal.com/).

Further, articles about the meeting are published in several medical journals and online medical news sources such as Diabetes Care, Metabolism, The Journal of Diabetes, Endocrine Practice, Diabetes and Vascular Disease Research, Endocrinology Today, Cardiology Today, Endocrine Web, Clinical Endocrinology News, Diabetes in Control, among others.

Program Objectives

The program is designed to evaluate both the clinical and basic science aspects of diabetes, obesity, HTN, dyslipidemia, CHF, CVD, CKD and related cardiometabolic conditions by focusing on insulin resistance, hyperinsulinemia, fat Inflammation and energy metabolism. The goal is to understand the pathophysiology of each condition and develop appropriate comprehensive clinical management plans.

 

Upon completion of this meeting, participants should be able to:

  • Describe the relationship between diabetes, obesity, and congestive heart failure

  • Discuss the effect of lipotoxicity and the pathophysiology of CVD

  • Discuss the role of obesity in the development of cardiometabolic conditions

  • Explain the roles of diabetes in the development of micro & macrovascular conditions: kidney disease, retinopathy, neuropathy, CVD and strokes

  • Provide comprehensive management of diabetes, through addressing obesity, hypertension, dyslipidemia and hyperglycemia

  • Discuss the role of incretins in the management of diabetes, obesity, and related complications

  • Evaluate the evidence supporting the use of SGLT2 inhibitors and GLP1ra's to reduce cardiovascular morbidity & mortality in patients with T2D and established CVD

  • Consider the role of SGLT2i & GLP1ra for primary prevention of cardiovascular morbidity & mortality in patients with T2D

  • Understand the role of PCSK9 inhibitors in preventing CV morbidity in people with established ASCVD

  • Understand fatty liver disease and its relationship to diabetes and CVD

  • Describe the pathogenesis of liver and muscle insulin resistance, the role of adipose tissue and of the mitochondria in hyperglycemia and ASCVD

  • Evaluate the impact on clinical practice of recent CVD, CHF & CKD outcome trials

  • Evaluate the impact on clinical practice of lipid CV outcome trials, including IMPROVE-IT, FOURIER, REDUCE-IT, ODYSSEY-Outcomes

  • Implement best practices for the prevention and management of CHF

  • Understand the Cardiorenal Syndrome

  • Examine the role of Coagulation and new anti-coagulation agents in prevention of CVD and CVA

  • Learn about reducing morbidity and mortality through being able to match the correct medications to the appropriate patients

Target Audience

This educational initiative is designed for cardiologists, endocrinologists, gastroenterologists, oncologists, internists, diabetologists, OBGYNs, pediatricians, dietitians, nurse practitioners, pharmacists, and any other health care professionals who are interested in improving patients outcome, focusing on insulin resistance, diabetes, obesity, cardiovascular disease, related Kidney and fatty liver morbidity, and potential prevention and management impact on health and society.

Program Chair

Yehuda Handelsman, MD is an Endocrinologist with extensive experience in the clinical aspect of Diabetes and CVD and is well-versed in managing Hyperglycemia, HTN, Lipid disorders and coagulation.

Dr. Handelsman is also an experienced clinical researcher and educator.

Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE

Chair & Program Director

Medical Director & Principal Investigator

Metabolic Institute of America 

Chair & Founder

International Committee for Insulin Resistance

Chair & Founder, International Lipid Forum

Tarzana, California

 

18372 Clark Street

Suite 212

Tarzana, CA 91356

info@tmioa.com

Phone: 818-342-1889
Fax: 818-342-1538

  • Facebook
  • Twitter

JOINTLY PROVIDED BY:

ADMINISTERED BY: